An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Conclude your understanding of lymphoma with an in-depth look at its signs and symptoms, from common indicators to subtle clues.

Speaker : Dr Suvir Singh

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr Vijay Agarwal ,Dr. Ananth Pai ,Dr. Sai Vivek ,Dr. Harish P

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr. Harish P ,Dr. Sai Vivek ,Dr. Ananth Pai ,Dr Vijay Agarwal

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr. Vijay Agarwal ,Dr. Ananth Pai ,Dr. Sai Vivek ,Dr. Harish P

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr. Harish P ,Dr. Sai Vivek ,Dr. Ananth Pai ,Dr Vijay Agarwal

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr Vijay Agarwal ,Dr. Ananth Pai ,Dr. Sai Vivek ,Dr. Harish P

Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2

Explore the impact of CDK4/6 inhibition in HR+/HER2- metastatic breast cancer, drawing insights from the pivotal PALOMA-2 study presented by Dr. Bhavna Parikh.

Speakers : Dr Bhavna Parikh

The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.

Discover the comprehensive impact of CDK4/6 inhibition in HR+/HER2- metastatic breast cancer, with key insights from the PALOMA-2 study presented by Dr. Bhavna Parikh.

Speakers : Dr Bhavna Parikh

Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.

Explore the multifaceted advantages of CDK4/6 inhibitors in HR+/HER2- breast cancer, based on the PALOMA-2 study, in this insightful session with Dr. Bhavna Parikh.

Speakers : Dr Bhavna Parikh

An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.

A detailed discussion on the benefits of using CDK4/6 inhibitors in HR+/ HER2-aBC in clinical trials.

Speakers : Dr. Bhavna Parikh

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV

The webinar gives insights into the role of pazopanib in managing renal cell carcinoma.

Speakers : Dr. Yogesh Kumar ,Dr. Pankaj Goyal ,Dr. Jatin Sarin ,Dr. Ankur Punia


Recommended News For You

fresh E. Coli Outbreak: ECMO Redefining Death and Bringing Universal Blood One Step Nearer.

World's premier cancer institute faces crippling cuts and chaos

In-person and Virtual Palliative Care Are Both Beneficial for Advanced Lung Cancer Patients.

FDA Approves Hemophilia B Second Gene Therapy.

Potential new therapy for childhood brain cancer could heal treatment-resistant tumors

Mutation Clearance After Transplant Linked to Better Outcomes in Myelofibrosis

Specialized imaging improves overall prostate cancer survival by identifying benefits of salvage radiotherapy

Recommended Articles For You

Unveiling the Mystery Behind Lymphovascular Invasion 

Colon cancer: Risk factors, warning signs and treatment options  

The benefits and risks of taking fludrocortisone for adrenal insufficiency  

Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study 
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Why preventive mastectomy isn't offered to everyone at risk

2.

Financial hardship common in patients with cancer

3.

Academics + Pharma = Big Bucks; New CAR-T Warnings; Patients Seek Cancer Tests.

4.

Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

5.

Severe obesity associated with reduced prevalence of recommended cancer screenings

1.

Sound Waves and Self-Destruction: A Promising Nanotech Weapon in the Fight Against Cancer

2.

Claudin-18.2 in Gastric Cancer: Tumor-Stroma Crosstalk and Disease Progression

3.

Real-World Oncology Insights: CAR-T, Immunotherapy, PROs, and Digital Tools

4.

Unleashing Precision Medicine: CRISPR-Cas9 Gene Editing in Hematopoietic Stem Cells

5.

Unveiling Tumor Immunity: Pan-Cancer Proteogenomics Characterization

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment

2.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V

3.

From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD

4.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

5.

Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot